Lord, Abbett & Co’s Relay Therapeutics RLAY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.54M Buy
473,358
+62,635
+15% +$1.2M 0.03% 415
2026
Q2
$7.68M Buy
+410,723
New +$5.96M 0.02% 422
2020
Q4
– Sell
-227,392
Closed -$9.7M – 693
2020
Q3
$9.7M Buy
+227,392
New +$8.67M 0.03% 478

Other funds holding RLAY

Lord, Abbett & Co's RLAY Position: Q3 2026 in Review

Lord, Abbett & Co increased its Relay Therapeutics (RLAY) stake by 15% in Q3 2026, buying an estimated $1.2M and bringing the position to 473,358 shares worth $8.54M. The position accounts for 0.03% of the portfolio, ranked #415.

Lord, Abbett & Co first reported a position in RLAY in Q3 2020 and has held it in 3 quarters since. The position peaked at $9.7M in Q3 2020. 261 funds tracked by Wall St. Rank hold RLAY as of Q3 2026.

  • Lord, Abbett & Co held 473,358 shares of Relay Therapeutics worth $8.54M as of Q3 2026.
  • Lord, Abbett & Co bought 62,635 Relay Therapeutics shares in Q3 2026, an estimated $1.2M.
  • Relay Therapeutics made up 0.03% of Lord, Abbett & Co's portfolio in Q3 2026, its #415 holding.
  • Lord, Abbett & Co first reported a position in Relay Therapeutics in Q3 2020 and has held it in 3 quarters since.
  • Lord, Abbett & Co's Relay Therapeutics position peaked at $9.7M in Q3 2020.
  • 261 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2026.

Based on Lord, Abbett & Co's 13F filing for Q3 2026, filed 13 Nov 2026.